Application of CXCR4-targeted tracer 68Ga-Pentixafor in lymphoma
10.3760/cma.j.cn321828-20240529-00182
- VernacularTitle:CXCR4靶向显像探针 68Ga-Pentixafor在淋巴瘤中的临床应用进展
- Author:
Xuebing YU
1
;
Fei KANG
1
Author Information
1. 空军军医大学第一附属医院核医学科，西安 710032
- Publication Type:Journal Article
- Keywords:
Lymphoma;
Chemokine CXCL12;
Positron-emission tomography;
68Ga-Pentixafor;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(6):381-384
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoma is a kind of hematological tumors with high heterogeneity, and the therapeutic regimen is closely dependent upon its accurate classification, staging and response evaluation. Despite 18F-FDG PET being recommended for the diagnosis and staging of lymphomas, the imaging effect of 18F-FDG PET is unacceptable for lymphoma with low 18F-FDG uptake. Recent studies have found that chemokine CXC subfamily receptor 4 (CXCR4) targeted PET has been widely used in the detection of tumors. 68Ga-Pentixafor, a cyclic pentapeptide analogue based on the structure of chemokine CXC ligand 12 (CXCL12; a specific ligand of CXCR4), has the advantages of high sensitivity and high tumor-to-background ratio in hematological tumor with low 18F-FDG uptake imaging compared with 18F-FDG. This review summarizes its application in the baseline evaluation, response evaluation, and prognosis prediction of lymphoma.
